Tamar Howson Net Worth

Tamar Howson biography

Tamar D. Howson serves as Independent Director of the Company. Ms. Howson is currently an Independent Director at MEI Pharma, Inc., and, until recently, was an Independent Director at Organovo Holdings, Inc. and Scientus Pharma. Earlier, she was a Senior Advisor on the transaction team at JSB-Partners, providing business development support to life sciences companies. Before that, she served as Executive Vice President, Corporate Business Development at Lexicon Pharmaceuticals, Inc. Prior, Ms. Howson was Senior Vice President, Corporate and Business Development at Bristol-Myers Squibb Company, responsible for worldwide oversight and management of the identification, evaluation and negotiation of mergers and acquisitions, licensing and other external alliance activities. Additionally, Ms. Howson spent nearly a decade at SmithKline Beecham, where she served as Senior Vice President and Director, Business Development and managed the company’s USD 100 million venture capital fund, SR One.

What is the salary of Tamar Howson?

As the Independent Director of Immunic, the total compensation of Tamar Howson at Immunic is $194,694. There are 10 executives at Immunic getting paid more, with Daniel Vitt having the highest compensation of $2,383,930.

How old is Tamar Howson?

Tamar Howson is 72, she's been the Independent Director of Immunic since 2019. There are no older and 15 younger executives at Immunic.

What's Tamar Howson's mailing address?

Tamar's mailing address filed with the SEC is 1200 AVENUE OF THE AMERICAS, SUITE 200, , NEW YORK, NY, 10036.

Insiders trading at Immunic

Over the last 5 years, insiders at Immunic have traded over $174,861 worth of Immunic stock and bought 176,506 units worth $558,583 . The most active insiders traders include Barclay A Phillips, Joerg Neermann e Duane Nash. On average, Immunic executives and independent directors trade stock every 74 days with the average trade being worth of $15,244. The most recent stock trade was executed by Daniel Vitt on 26 February 2024, trading 14,000 units of IMUX stock currently worth $18,340.

What does Immunic do?

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

Immunic executives and stock owners

Immunic executives and other stock owners filed with the SEC include:

• Daniel Vitt,
  President, Chief Executive Officer, Director
• Andreas Muehler,
  Chief Medical Officer
• Manfred Groppel,
  Chief Operating Officer
• Dr. Daniel Vitt,
  CEO, Pres & Director
• Dr. Andreas Muehler Ph.D., M.D.,
  Chief Medical Officer
• Glenn Whaley,
  VP of Fin. and Principal Financial & Accounting Officer
• Dr. Duane D. Nash M.B.A., M.D., J.D., M.B.A,
  Exec. Chairman
• Jan Van den Bossche,
  Independent Director
• Jorg Neermann,
  Independent Director
• Vincent Ossipow,
  Independent Director
• Tamar Howson,
  Independent Director
• Barclay Phillips,
  Independent Director
• Jessica Breu,
  IR Contact Officer
• Hella Kohlhof,
  Chief Scientific Officer
• Glenn Whaley,
  Vice President Finance, Principal Financial and Accounting Officer
• Patrick Walsh,
  Chief Bus. Officer
• Inderpal Singh,
  Gen. Counsel
• Dr. Hella Kohlhof,
  Chief Scientific Officer
• Dr. Manfred Gröppel,
  Co-Founder & COO
• Jason Tardio,
  President and COO
• Richard Alan Rudick,
  Director
• Sanjay S Patel,
  Chief Financial Officer
• Joerg Neermann,
  Director
• Manfred Groeppel,
  Chief Operating Officer
• Duane Nash,
  Executive Chairman
• Monika Maria Toernsen,
  Director
• Simona Skerjanec,
  Director